When site-specific trial stratification is a bad idea

The experience of one small-cap biotech shows that relying on a single statistical analysis method, even if that method is suggested by regulators, is not always the best approach to interpreting a dataset.

German biotech InflaRx N.V. (NASDAQ:IFRX) had a solid mechanistic rationale for why its C5a inhibitor vilobelimab might work in patients with severe COVID-19: the inhibitor blocks neutrophil activation, which is implicated as a major driver of the inflammatory cascade that eventually leads to microangiopathy and thrombosis in severe COVID-19. ...